-+ 0.00%
-+ 0.00%
-+ 0.00%

Kailera Q1 FY26 net loss more than quadruples to $78.87 million

PUBT·05/26/2026 20:02:51
Listen to the news
Kailera Q1 FY26 net loss more than quadruples to $78.87 million
  • Kailera posted a net loss of $78.87 million in Q1 2026, widening from a $17.98 million loss a year earlier.
  • Research and development expenses more than doubled to $70.87 million, while general and administrative costs rose 33.88% to $13.79 million.
  • Cash, cash equivalents and marketable securities totaled $581.9 million as of March 31, with IPO proceeds expected to fund operations into mid-2028.
  • Advanced obesity pipeline with five late-stage global trials initiated, including the KaiNETIC Phase 3 program for once-weekly ribupatide injection.
  • Reported new partner-led topline data in China for oral GLP-1 agonist KAI-7535 in type 2 diabetes and first-in-human Phase 1 results for injectable tri-agonist KAI-4729.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605261602PRIMZONEFULLFEED9726706) on May 26, 2026, and is solely responsible for the information contained therein.